DE69620866T2 - Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen - Google Patents

Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen

Info

Publication number
DE69620866T2
DE69620866T2 DE69620866T DE69620866T DE69620866T2 DE 69620866 T2 DE69620866 T2 DE 69620866T2 DE 69620866 T DE69620866 T DE 69620866T DE 69620866 T DE69620866 T DE 69620866T DE 69620866 T2 DE69620866 T2 DE 69620866T2
Authority
DE
Germany
Prior art keywords
pct
lactam antibiotic
granulate
date aug
oral doses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69620866T
Other languages
English (en)
Other versions
DE69620866D1 (de
Inventor
Jan SIJBRANDS
Koutrik Cornelis Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Europe BV
Original Assignee
Yamanouchi Europe BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Europe BV filed Critical Yamanouchi Europe BV
Application granted granted Critical
Publication of DE69620866D1 publication Critical patent/DE69620866D1/de
Publication of DE69620866T2 publication Critical patent/DE69620866T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DE69620866T 1995-02-08 1996-02-08 Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen Expired - Lifetime DE69620866T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200313 1995-02-08
PCT/EP1996/000547 WO1996024337A1 (en) 1995-02-08 1996-02-08 ORAL DOSAGE-FORMS CONTAINING A β-LACTAM ANTIBIOTIC

Publications (2)

Publication Number Publication Date
DE69620866D1 DE69620866D1 (de) 2002-05-29
DE69620866T2 true DE69620866T2 (de) 2003-02-27

Family

ID=8220003

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620866T Expired - Lifetime DE69620866T2 (de) 1995-02-08 1996-02-08 Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen

Country Status (19)

Country Link
US (1) US5948422A (de)
EP (1) EP0801559B1 (de)
CN (1) CN1125636C (de)
AT (1) ATE216576T1 (de)
AU (1) AU4789696A (de)
BG (1) BG63528B1 (de)
BR (1) BR9607189A (de)
CZ (1) CZ293718B6 (de)
DE (1) DE69620866T2 (de)
DK (1) DK0801559T3 (de)
EA (2) EA003736B1 (de)
ES (1) ES2175073T3 (de)
HU (1) HU227938B1 (de)
MX (1) MX9706062A (de)
NO (1) NO319993B1 (de)
PL (1) PL186386B1 (de)
PT (1) PT801559E (de)
WO (1) WO1996024337A1 (de)
ZA (1) ZA961018B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
SK3999A3 (en) * 1996-07-16 1999-07-12 Gist Brocades Nv 'beta'-lactam granules free of organic solvents
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
WO1999044580A1 (en) * 1998-03-06 1999-09-10 Eurand International S.P.A. Fast disintegrating tablets
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
DE19922537A1 (de) * 1999-05-10 2000-11-16 Roland Bodmeier Darreichungsform zur Applikation in Körperöffnungen
WO2002024230A1 (fr) * 2000-09-22 2002-03-28 Takeda Chemical Industries, Ltd. Preparations solides
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
CZ20032138A3 (cs) * 2001-02-05 2005-03-16 R. P. Scherer Technologies, Inc. Způsoby a prostředky pro zeslabení chuti farmaceuticky aktivních činidel
AU2003220058B2 (en) * 2002-03-12 2008-05-01 Toyama Chemical Company Limited Palatable oral suspension and method
MXPA05003357A (es) * 2002-10-02 2005-06-22 Meiji Seika Kaisha Composicion medicinal antibacteriana de capacidad de absorcion oral mejorada.
EP1578422B1 (de) * 2002-12-20 2007-04-11 NicoNovum AB Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
CA2531022C (en) * 2003-07-03 2014-09-09 Jannette Dufour Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
CA2626933C (en) 2005-11-17 2015-12-29 Novartis Ag Pharmaceutical composition
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CA2658951A1 (en) * 2006-07-28 2008-01-31 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof
WO2010031552A1 (en) * 2008-09-17 2010-03-25 Niconovum Ab Process for preparing snuff composition
US20120111756A1 (en) * 2008-12-17 2012-05-10 Altheus Therapeutics, Inc. Enema formulations
WO2023204773A1 (en) * 2022-04-20 2023-10-26 Bilim Ilac Sanayii Ve Ticaret A.S. Tablet formulations for the treatment of urinary system infections and method for the preparation of such formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3344030A (en) * 1964-06-15 1967-09-26 American Home Prod Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
DE2251249A1 (de) * 1972-10-19 1974-05-02 Hoechst Ag Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
ES2060737T3 (es) * 1988-02-25 1994-12-01 Yamanouchi Europ Bv Procedimiento de preparacion de un granulado farmaceutico.
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
AU715177B2 (en) * 1994-04-13 2000-01-20 Research Corporation Technologies, Inc. Methods of treating disease using sertoli cells and allografts or xenografts
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin

Also Published As

Publication number Publication date
NO973646L (no) 1997-09-11
BR9607189A (pt) 1997-11-11
DK0801559T3 (da) 2002-06-17
AU4789696A (en) 1996-08-27
HUP9801677A2 (hu) 1998-11-30
HU227938B1 (en) 2012-06-28
PL186386B1 (pl) 2004-01-30
NO319993B1 (no) 2005-10-10
EA199700093A1 (ru) 1998-02-26
ES2175073T3 (es) 2002-11-16
CZ293718B6 (cs) 2004-07-14
EA000361B1 (ru) 1999-06-24
PT801559E (pt) 2002-09-30
US5948422A (en) 1999-09-07
WO1996024337A1 (en) 1996-08-15
CN1125636C (zh) 2003-10-29
EP0801559A1 (de) 1997-10-22
NO973646D0 (no) 1997-08-07
EP0801559B1 (de) 2002-04-24
EA199900205A1 (ru) 2000-06-26
CZ230297A3 (en) 1997-11-12
CN1173816A (zh) 1998-02-18
ATE216576T1 (de) 2002-05-15
HUP9801677A3 (en) 1999-05-28
ZA961018B (en) 1997-08-08
PL321567A1 (en) 1997-12-08
EA003736B1 (ru) 2003-08-28
BG101822A (en) 1998-04-30
BG63528B1 (bg) 2002-04-30
DE69620866D1 (de) 2002-05-29
MX9706062A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
DE69620866T2 (de) Vehrfahren zur herstellung von beta-lactam antibiotikum enthaltenden oralen dosisformen
ATE244004T1 (de) Pharmazeutische zubereitung enthaltend metformin und verfahren zu deren herstellung
ZA965237B (en) A composition and a process for the preparation thereof
IL115920A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING omega-SUBSTITUTED 2,2-DICHLOROALKANECARBOXYLIC ACIDS, SOME SUCH NEW COMPOUNDS AND PROCESS FOR THEIR PREPARATION
GR3036117T3 (en) Medicated chewing gum with a pleasant taste containing an inclusion complex
HUT72970A (en) Risperidone pamoate, pharmaceutical composition containing it and process for their production
HUT50842A (en) Process for producing new diphosphonic acid derivatives and pharmaceutical compositions comprising same
DE59604175D1 (de) Verfahren zur herstellung von celluloselösungen in wasserhaltigen tertiären amin-n-oxiden
ATE60711T1 (de) Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
HUP9601358A2 (en) Fluoro-phenyl-substituted alkenyl-carboxylic-guanidines, process for producing them, their use as medicines or diagnostica, and pharmaceutical compositions containing them
HU9601321D0 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them
HUP9602640A2 (en) Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds.
NZ332545A (de)
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
ATE173922T1 (de) 2-arylpropionsäure-zubereitungen und verfahren zu ihrer herstellung
HU9503345D0 (en) Substituted benzoyl-guanidine derivatives, process for producing them their use as medicine and diagnosticum and pharmaceutical composition containing them
DE69102143T2 (de) Spiramycin enthaltende arzneimittel und verfahren zu deren herstellung.
GR3031544T3 (en) New derivatives of pyridine or pyridazine, process for production thereof and medicaments containing these compounds
IL64839A0 (en) Base-substituted anthranilic acids,a process for their preparation and their use
TW334424B (en) L-arginine aldehyde derivatives process for preparing them and pharmaceutical composition
ATE66468T1 (de) Leukotrienantagonisten, verfahren zu ihrer herstellung und ihre anwendung zur behandlung von krankheiten.
IL117734A0 (en) Beta-carbolines and pharmaceutical compositions containing them
ATE32514T1 (de) 3-(4'-aminobutylamino)-propylamino-bleomycinderivate, verfahren zur ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
HUP9902478A2 (hu) Vírusellenes gyógyszerkészítmények és eljárás azok előállítására

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA EUROPE B.V., LEIDERDORP, NL